RxDoctor Payments Data

Christopher Cotton, MD

General Practice · Denver City, TXNPI 1841271681

Payments from drug & device makers

$1,164in general payments, 2019–2025

Across 20 payments — averaging $58.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$726
  • Astellas Pharma US Inc$174
  • Lilly USA, LLC$57
  • AbbVie$53
  • Pfizer$46
  • Novo Nordisk$33
  • plus $74 from 4 others

What the payments were for

  • Travel & lodging$72662%
  • Food & beverage$28224%
  • Education$15613%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,164 in reported general payments places this provider in the 85th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Medicare billing

Part B allowed, 2024
$5,937
Medicare patients
20
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin172$138,732
EliquisApixaban180$119,792
FarxigaDapagliflozin Propanediol121$83,544
MounjaroTirzepatide49$59,152
TrulicityDulaglutide60$56,865
GlyxambiEmpagliflozin/Linagliptin47$53,644
OzempicSemaglutide45$44,935
JanuviaSitagliptin Phosphate60$40,348
TradjentaLinagliptin53$36,886
Tresiba Flextouch U-100Insulin Degludec37$26,404
Trijardy XrEmpaglifloz/Linaglip/Metformin44$24,997
RybelsusSemaglutide22$21,953
JanumetSitagliptin Phos/Metformin Hcl32$21,817
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen430$15,422
Spiriva HandihalerTiotropium Bromide15$14,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$119,792180 claims
Lilly USA, LLCMounjaro, Trulicity$57$116,018109 claims
Novo NordiskOzempic, Rybelsus$33$66,88867 claims
Astellas Pharma US IncMyrbetriq$174$7,08515 claims
AbbVieLinzess$53$6,87111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,074 general practice providers in Texas.

Other general practice in Denver City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →